ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT06477952

DRonabinol Treatment of OSA

Targeted Treatment of Obstructive Sleep Apnea With Dronabinol: Proof of Concept and Phase II Clinical Trial

Sponsor

VA Office of Research and Development

Enrollment

120 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Obstructive Sleep Apnea

Summary

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Eligibility

Max Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dronabinol for people with obstructive sleep apnea. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDronabinol

Open label Dronabinol treatment for two weeks.

Locations(1)

Jesse Brown VA Medical Center, Chicago, IL

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06477952

Related Trials

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

NCT063903455 locations

Identification of Biomarkers of Obstructive Sleep Apnea.

NCT077231441 location

Myofunctional Therapy for Obstructive Sleep Apnea

NCT073011251 location

Rescue Pharmacotherapy for OSA

NCT052936001 location

Comparative Assessment of Sleep Positive Airway Pressure Modalities (CASPAM)

NCT065648961 location